New Trial of treatment for people with Idiopathic Pulmonary Fibrosis 5th December 2016

The STH Interstitial Lung Disease service led by Dr Stephen Bianchi has initiated a clinical trial sponsored by Boehringer-Ingelheim. The trial will investigate if combining two drugs, Nintedanib and Sildenafil, is effective in treatment of idiopathic lung fibrosis (IPF). Nintedanib is approved in the UK for treatment of IPF. Sildenafil has not yet been approved for IPF, but it has been approved for the treatment of adults with pulmonary arterial hypertension. The trial will be supported by the STH Respiratory Physiology Department, as well as the Diagnostic Cardiology and NGH Clinical Research Facility teams. For more info contact the CRF via